Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(29%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_3
3
43%
Ph phase_2
3
43%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(2)

Detailed Status

Not yet recruiting3
Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

not_yet_recruiting343%
recruiting229%
completed229%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_2

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

NCT07562711
not_yet_recruitingphase_3

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

NCT07472868
not_yet_recruitingphase_2

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

NCT07353827
not_yet_recruitingphase_3

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

NCT06783491
recruitingphase_2

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

NCT06860477
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07562711Phase 2

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

Recruiting
NCT07472868Phase 3

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT07353827Phase 2

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Not Yet Recruiting
NCT06783491Phase 3

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not Yet Recruiting
NCT06860477Phase 2

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

Recruiting
NCT00399035Phase 3

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

Completed
NCT00494221Phase 1

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7